194 related articles for article (PubMed ID: 18444869)
21. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
[TBL] [Abstract][Full Text] [Related]
22. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Tebas P; Zhang J; Hafner R; Tashima K; Shevitz A; Yarasheski K; Berzins B; Owens S; Forand J; Evans S; Murphy R
J Antimicrob Chemother; 2009 May; 63(5):998-1005. PubMed ID: 19299471
[TBL] [Abstract][Full Text] [Related]
23. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity.
Sánchez-Conde M; de Mendoza C; Jiménez-Nacher I; Barreiro P; Gonzalez-Lahoz J; Soriano V
HIV Clin Trials; 2005; 6(4):197-202. PubMed ID: 16214736
[TBL] [Abstract][Full Text] [Related]
24. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.
Domingo P; Gutierrez Mdel M; Gallego-Escuredo JM; Torres F; Mateo GM; Villarroya J; de los Santos I; Domingo JC; Villarroya F; Del Rio L; Estrada V; Giralt M
PLoS One; 2014; 9(2):e89088. PubMed ID: 24586518
[TBL] [Abstract][Full Text] [Related]
25. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
26. Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).
Feeney ER; Chazallon C; O'Brien N; Meiffrédy V; Goodall RL; Aboulker JP; Cooper DA; Yeni P; Mallon PW;
HIV Med; 2011 Nov; 12(10):602-9. PubMed ID: 21599820
[TBL] [Abstract][Full Text] [Related]
27. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
Boyd MA; Carr A; Ruxrungtham K; Srasuebkul P; Bien D; Law M; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange JM; Phanuphak P; Cooper DA; Reiss P
J Infect Dis; 2006 Sep; 194(5):642-50. PubMed ID: 16897663
[TBL] [Abstract][Full Text] [Related]
28. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
[TBL] [Abstract][Full Text] [Related]
29. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
[TBL] [Abstract][Full Text] [Related]
30. Low dose versus high dose stavudine for treating people with HIV infection.
Magula N; Dedicoat M
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007497. PubMed ID: 25627012
[TBL] [Abstract][Full Text] [Related]
31. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.
McComsey GA; O'Riordan M; Setzer B; Lebrecht D; Baron E; Walker UA
Eur J Clin Nutr; 2008 Aug; 62(8):1031-7. PubMed ID: 17538545
[TBL] [Abstract][Full Text] [Related]
32. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
[TBL] [Abstract][Full Text] [Related]
33. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Ribera E; Larrousse M; Curran A; Negredo E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Ferrer P; Alvarez ML; Arterburn S; Martínez E
HIV Med; 2013 Jul; 14(6):327-36. PubMed ID: 23298339
[TBL] [Abstract][Full Text] [Related]
34. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170.
Skiest DJ; Krambrink A; Su Z; Robertson KR; Margolis DM;
J Acquir Immune Defic Syndr; 2008 Dec; 49(4):377-83. PubMed ID: 18931631
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
[TBL] [Abstract][Full Text] [Related]
36. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
Hammond E; McKinnon E; Nolan D
Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
[TBL] [Abstract][Full Text] [Related]
37. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274
[TBL] [Abstract][Full Text] [Related]
38. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
Lonergan JT; McComsey GA; Fisher RL; Shalit P; File TM; Ward DJ; Williams VC; Hessenthaler SM; Lindsey L; Hernandez JE;
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):935-42. PubMed ID: 15220700
[TBL] [Abstract][Full Text] [Related]
39. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
